WO2007118051A3 - Lipid therapy - Google Patents
Lipid therapy Download PDFInfo
- Publication number
- WO2007118051A3 WO2007118051A3 PCT/US2007/065791 US2007065791W WO2007118051A3 WO 2007118051 A3 WO2007118051 A3 WO 2007118051A3 US 2007065791 W US2007065791 W US 2007065791W WO 2007118051 A3 WO2007118051 A3 WO 2007118051A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition including
- abcal
- hdl
- high density
- density lipoprotein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0456—Lipoprotein
Abstract
A method including introducing into a blood stream a delipidated high density lipoprotein (HDL) and a bioactive agent. A composition including a delipidated high density lipoprotein (HDL) and an auxiliary agent in a form suitable for delivery into a blood vessel. A composition including Apo Al comprising a hydrophobic ligand suitable to interact with cell surface binding sites. A composition including Apo Al and an agent selected to one of increase the ATP-binding cassette protein 1 (ABCAl) transporter expression in macrophages and protect ABCAl from thiol-mediated degradation.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78904906P | 2006-04-03 | 2006-04-03 | |
US60/789,049 | 2006-04-03 | ||
US11/694,793 US8785382B2 (en) | 2006-04-03 | 2007-03-30 | Lipid therapy |
US11/694,793 | 2007-03-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007118051A2 WO2007118051A2 (en) | 2007-10-18 |
WO2007118051A3 true WO2007118051A3 (en) | 2008-07-24 |
Family
ID=38521852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/065791 WO2007118051A2 (en) | 2006-04-03 | 2007-04-02 | Lipid therapy |
Country Status (2)
Country | Link |
---|---|
US (2) | US8785382B2 (en) |
WO (1) | WO2007118051A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9504209B2 (en) | 2010-04-09 | 2016-11-29 | Rain Bird Corporation | Irrigation sprinkler nozzle |
US10441531B2 (en) | 2012-11-09 | 2019-10-15 | Bloodworks | Protein stabilizing factors |
KR101826792B1 (en) * | 2015-10-29 | 2018-02-09 | 주식회사 와이바이오로직스 | Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of delta-like 1 homolog |
US11247219B2 (en) | 2019-11-22 | 2022-02-15 | Rain Bird Corporation | Reduced precipitation rate nozzle |
JPWO2023058657A1 (en) * | 2021-10-04 | 2023-04-13 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004017946A1 (en) * | 2002-08-26 | 2004-03-04 | Lipid Sciences, Inc. | Treating alzheimers using delipidated protein particles |
US20050133450A1 (en) * | 2001-06-25 | 2005-06-23 | Bomberger David C. | Hollow fiber contactor systems for removal of lipids from fluids |
US20060172939A1 (en) * | 2003-07-03 | 2006-08-03 | Marc Bellotti | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5911698A (en) * | 1995-12-22 | 1999-06-15 | Aruba International Pty. Ltd. | Treatment for cardiovascular and related diseases |
WO2001054748A1 (en) * | 2000-01-25 | 2001-08-02 | Edwards Lifesciences Corporation | Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia |
US6527801B1 (en) | 2000-04-13 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Biodegradable drug delivery material for stent |
IL161110A0 (en) * | 2001-09-28 | 2004-08-31 | Esperion Therapeutics Inc | Prevention and treatment of restenosis by local admistration of drug |
US20050019404A1 (en) | 2003-06-30 | 2005-01-27 | Hsing-Wen Sung | Drug-eluting biodegradable stent |
PT1641421T (en) | 2003-07-03 | 2019-03-27 | Hdl Therapeutics Inc | Methods and apparatus for creating particle derivatives of hdl with reduced lipid content |
US7959659B2 (en) | 2004-01-02 | 2011-06-14 | Advanced Cardiovascular Systems, Inc. | High-density lipoprotein coated medical devices |
US8097283B2 (en) * | 2004-01-15 | 2012-01-17 | Mount Sinai School Of Medicine | Methods and compositions for imaging |
US9283099B2 (en) | 2004-08-25 | 2016-03-15 | Advanced Cardiovascular Systems, Inc. | Stent-catheter assembly with a releasable connection for stent retention |
-
2007
- 2007-03-30 US US11/694,793 patent/US8785382B2/en not_active Expired - Fee Related
- 2007-04-02 WO PCT/US2007/065791 patent/WO2007118051A2/en active Application Filing
-
2014
- 2014-06-09 US US14/299,771 patent/US9358268B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050133450A1 (en) * | 2001-06-25 | 2005-06-23 | Bomberger David C. | Hollow fiber contactor systems for removal of lipids from fluids |
WO2004017946A1 (en) * | 2002-08-26 | 2004-03-04 | Lipid Sciences, Inc. | Treating alzheimers using delipidated protein particles |
US20060172939A1 (en) * | 2003-07-03 | 2006-08-03 | Marc Bellotti | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
Also Published As
Publication number | Publication date |
---|---|
US20070232539A1 (en) | 2007-10-04 |
US20140287033A1 (en) | 2014-09-25 |
WO2007118051A2 (en) | 2007-10-18 |
US9358268B2 (en) | 2016-06-07 |
US8785382B2 (en) | 2014-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007118051A3 (en) | Lipid therapy | |
Asztalos et al. | Metabolic and functional relevance of HDL subspecies | |
Zhao et al. | Relative roles of various efflux pathways in net cholesterol efflux from macrophage foam cells in atherosclerotic lesions | |
Simonsen | Evaluation of reconstituted high-density lipoprotein (rHDL) as a drug delivery platform–a detailed survey of rHDL particles ranging from biophysical properties to clinical implications | |
Jessup et al. | Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages | |
Echeverry et al. | Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus | |
Han et al. | Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene | |
Luthi et al. | Robust passive and active efflux of cellular cholesterol to a designer functional mimic of high density lipoprotein | |
WO2005079290A3 (en) | Hybrid contact lens system and method | |
WO2001052833A8 (en) | Compositions for delivery of a cortisol antagonist | |
WO2003092633A3 (en) | Diffusion-controlled dosage form and method of fabrication including three dimensional printing | |
WO2005117557A3 (en) | Expression system | |
WO2010129023A3 (en) | Supercharged proteins for cell penetration | |
WO2006015386A3 (en) | A method of making a coated medical device | |
GB0906137D0 (en) | Structure enclosing hematopoietic progenitor cells from ES cells and method for preparing blood cells using the same | |
Liao et al. | Hyperhomocysteinemia and high-density lipoprotein metabolism in cardiovascular disease | |
WO2006021160A8 (en) | Butylbenzene phthalein self-emulsifying drug delivery system, its preparation method and application | |
MX2008015337A (en) | Method and compound for the treatment of valvular stenosis. | |
EP1644802A4 (en) | Dual virtual machine and trusted platform module architecture for next generation media players | |
Tang et al. | Influence of route of administration and lipidation of apolipoprotein AI peptide on pharmacokinetics and cholesterol mobilization | |
WO2008070721A3 (en) | High protein concentration formulations containing mannitol | |
IL194775A (en) | Pharmaceutical compositions comprising an antisecretory protein for use in the treatment and/or prevention of dysfunction of lipid rafts and/or caveolae | |
Brown | High-density lipoprotein and transport of cholesterol and triglyceride in blood | |
Pedersen et al. | Lipoprotein (a) accelerates atherosclerosis in uremic mice [S] | |
Martinez-Mier et al. | Living related kidney transplantation without calcineurin inhibitors: initial experience in a Mexican center |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07759963 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07759963 Country of ref document: EP Kind code of ref document: A2 |